文献速递造血干细胞移植与细胞治疗

HLA-B外显子1在无关供者造血细胞移植后GVHD中的作用:回顾性队列研究

Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study.
PubMed 文献 · Lancet Haematol · 2019-10-25

该回顾性队列研究纳入1988至2016年在多地区接受无关供者造血细胞移植的33 982例患者,评估HLA-B前导序列二态性(M/T)对GVHD风险的影响。

核心结论

  • HLA-B前导序列可预测HLA-B错配无关供者HCT后的GVHD风险,并区分高风险与低风险错配。
  • 匹配同种异型的前导序列可能与错配同种异型的前导序列同等重要。
  • 前瞻性识别前导序列匹配的供者对多数需要HCT的患者可行,可能降低GVHD并提高移植可及性。

研究设计与样本

  • 数据来自国际组织相容性工作组造血细胞移植参与者,无排除标准。
  • 采用多变量回归模型评估HLA-A、HLA-B、HLA-C、HLA-DRB1和HLA-DQB1错配相关风险。
  • 前导序列频率在2 004 742例BeTheMatch美国登记供者中定义。

主要发现

  • 中位随访1841天(IQR 909-2963)。
  • 死亡和GVHD风险随HLA错配数量增加而升高。

关键数值与推荐

  • 首选的HLA-B错配供者为前导序列匹配且共享T前导序列同种异型。

临床怎么用

  • 在HLA-B错配无关供者HCT中,应考虑HLA-B前导序列匹配以降低GVHD风险。
  • 优先选择前导序列匹配且共享T前导序列同种异型的供者。
  • 对多数需要HCT的患者,前瞻性识别前导序列匹配的供者可行。

局限性

  • 本研究为回顾性队列研究。
  • 研究结果需在前瞻性试验中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The success of unrelated haemopoietic cell transplantation (HCT) is limited by graft-versus-host disease (GVHD), which is the main post-transplantation challenge when HLA-matched donors are unavailable. A sequence dimorphism in exon 1 of HLA-B gives rise to leader peptides containing methionine (Met; M) or threonine (Thr; T), which differentially influence natural killer and T-cell alloresponses. The main aim of the study was to evaluate the role of the leader dimorphism in GVHD after HLA-B-mismatched unrelated HCT. METHODS: We did a retrospective cohort study of 33 982 patients who received an unrelated HCT done in Australia, Europe, Japan, North America, and the UK between Jan 1, 1988, and Dec 31, 2016. Data were contributed by participants of the International Histocompatibility Working Group in Hematopoietic Cell Transplantation. All cases were included and there were no exclusion criteria. Multivariate regression models were used to assess risks associated with HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 mismatching. Among the 33 982 transplantations, the risks of GVHD associated with HLA-B M and T leaders were established in 17 100 (50·3%) HLA-matched and 1457 (4·3%) single HLA-B-mismatched transplantations using multivariate regression models. Leader frequencies were defined in 2 004 742 BeTheMatch US registry donors. FINDINGS: Between Jan 20, 2017, and March 11, 2019, we assessed 33 982 HCTs using multivariate regression models for the role of HLA mismatching on outcome. Median follow-up was 1841 days (IQR 909-2963). Mortality and GVHD increased with increasing numbers of HLA mismatches. A single HLA-B mismatch increased grade 3-4 acute GVHD (odds ratio [OR] 1·89, 95% CI 1·53-2·33; p<0·0001). Among the single HLA-B-mismatched transplantations, acute GVHD risk was higher with leader mismatching than with leader matching (OR 1·73, 1·02-2·94; p=0·042 for grade 2-4) and with an M leader shared allotype compared with a T leader shared allotype (OR 1·98, 1·39-2·81; p=0·0001 for grade 3-4). The preferred HLA-B-mismatched donor is leader-matched and shares a T leader allotype. The majority (1 836 939 [91·6%]) of the 2 004 742 US registry donors have the TT or MT genotype. INTERPRETATION: The HLA-B leader informs GVHD risk after HLA-B-mismatched unrelated HCT and differentiates high-risk HLA-B mismatches from those with lower risk. The leader of the matched allotype could be considered to be as important as the leader of the mismatched allotype for GVHD. Prospective identification of leader-matched donors is feasible for most patients in need of a HCT, and could lower GVHD and increase availability of HCT therapy. These findings are being independently validated and warrant further research in prospective trials. FUNDING: The National Institutes of Health, USA.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Petersdorf EW, Carrington M, O'hUigin C, et al. Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study. Lancet Haematol. 2019. PMID: 31669248. doi:10.1016/S2352-3026(19)30208-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。